[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351312-105":59,"doc-detail-351312-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","baseline-tumor-burden-and-outcomes-in-patients-with-rare-cancers-treated-with-immunotherapy-southwest-oncology-group-trial-s1609","Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)","","Baseline tumor burden may be linked to immune checkpoint inhibitor (ICI) outcomes, but evidence across rare cancers remains limited. This study assessed whether pretreatment tumor burden predicts overall survival (OS), progression-free survival (PFS), and tumor regression in patients with rare cancers treated with dual ICIs. Using Southwest Oncology Group trial S1609, 722 patients with measurable disease were analyzed with tumor burden quartiles and target lesion counts as predictors. Larger burden correlated with shorter OS, while PFS showed no clear association.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/baseline-tumor-burden-and-outcomes-in-patients-with-rare-cancers-treated-with-immunotherapy-southwest-oncology-group-trial-s1609/351312/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/baseline-tumor-burden-and-outcomes-in-patients-with-rare-cancers-treated-with-immunotherapy-southwest-oncology-group-trial-s1609/351312.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How is baseline tumor burden defined in this study?","Question",{"text":112,"@type":113},"Baseline tumor burden is defined as the sum of the greatest dimensions of target lesions at study registration. The number of target lesions is also considered a secondary tumor burden measure.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What endpoints were used to evaluate outcomes?",{"text":117,"@type":113},"Overall survival (OS) and progression-free survival (PFS) were the primary endpoints, with tumor regression assessed at first scan.",{"name":119,"@type":110,"acceptedAnswer":120},"What was the relationship between baseline tumor burden and survival?",{"text":121,"@type":113},"Larger baseline tumor burden correlated with shorter OS, but not with PFS. Tumor regression showed only a weak negative association with higher baseline tumor burden quartiles at first scan.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351312,1790641812,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","DOI: 10. 1002/cncr.70374  \nORIGINAL ARTICLE  \nBaseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)  \nPaul L. Swiecicki MD 1  | Megan Othus PhD2,3 | Sandip P. Patel MD4 | Young Kwang-Chae MD, MPH, MBA5 | Razelle Kurzrock MD6  \n1University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, USA  \n2Southwest Oncology Group Cancer Research Network Statistical Center, Seattle, Washington, USA  \n3Fred Hutchinson Cancer Center, Seattle, Washington, USA  \n4University of California at San Diego Moores Cancer Center, La Jolla, California, USA 5Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA  \n6Medical College of Wisconsin, Milwaukee, Wisconsin, USA  \nCorrespondence  \nPaul L. Swiecicki, University of Michigan Rogel Cancer Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.  \nEmail: [pswiecic@med.umich.edu](pswiecic@med.umich.edu)  \nFunding information  \nNational Cancer Institute, Grant/Award Numbers: 5U01CA180888-08, 5UG1CA233198-05, U10CA180819, U10CA180888  \nABSTRACT  \nBackground: It has been suggested that baseline tumor burden may correlate with immune checkpoint inhibitor (ICI) outcome for individual tumor types in which ICIs are standardly used. The authors investigated whether pretreatment tumor burden correlates with overall survival (OS), progression-free survival (PFS), and tumor regression among patients who had rare cancers treated with dual ICIs.  \nMethods: Southwest Oncology Group study S1609 was a phase 2, National Cancer Institute/Southwest Oncology Group basket study (> 1000 sites) evaluating nivolumab plus ipilimumab in 53 cohorts of patients who had rare/ultrarare malignancies ([ClinicalTrials.gov](ClinicalTrials.gov) identifier NCT02834013). Overall, 722 patients were included in this secondary analysis, all of whom had measurable disease (Response Evaluation Criteria in Solid Tumors, version 1. 1). Baseline tumor burden, defined asthe sum of the greatest dimensions of target lesions at study registration, was analyzed based on quartiles observed in the data. The number of target lesions was also considered a secondary tumor burden measure. End points included OSand PFS.  \nResults: Larger baseline tumor burden correlated with shorter OS, but not PFS (multivariable analysis). Higher baseline tumor burden quartiles had only a weak negative association with any tumor regression at first scan (Fisher exact test, p = .09), and multivariable analyses further indicated that both tumor burden and any tumor regression at first posttreatment scan were independently associated with OS in multivariable analysis (comparing a baseline tumor size ≥12.9 cm vs. 1.0–4.8 cm; hazard ratio, 1. 64; 95% confidence interval, 1.02–1. 72; p = .032), but there was no evidence of an interaction between tumor burden and any tumor regression at the first scan (p for interaction > . 65).  \nConclusions: Larger baseline tumor burden was associated with worse OS, but not PFS, and was not predictive of tumor regression after dual ICI therapy in a large cohort with rare cancer types.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2026 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.  \nCancer. 2026;e70374.  \n[https://doi.org/10.1002/cncr.70374](https://doi.org/10.1002/cncr.70374)  \nwi[leyonlinelibrary.com/journal/cncr](leyonlinelibrary.com/journal/cncr)  \n1 of 8  \nKEYWORDS  \nimmune checkpoint inhibitor, immunotherapy, predictive biomarkers, rare cancers, Response Evaluation Criteria in Solid Tumors (RECIST), Southwest Oncology Group study S1609, tumor burden  \nINTRODUCTION  \nThe advent of immune checkpoint inhibitors (ICIs) has revolutionized the management of many solid tumors, resulting in new treatment paradigms, less treatment-r","cbCaicSHBntDXOgp","https://ap.wps.com/l/cbCaicSHBntDXOgp","pdf",976690,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Materials and Methods","[{\"question\":\"How is baseline tumor burden defined in this study?\",\"answer\":\"Baseline tumor burden is defined as the sum of the greatest dimensions of target lesions at study registration. The number of target lesions is also considered a secondary tumor burden measure.\"},{\"question\":\"What endpoints were used to evaluate outcomes?\",\"answer\":\"Overall survival (OS) and progression-free survival (PFS) were the primary endpoints, with tumor regression assessed at first scan.\"},{\"question\":\"What was the relationship between baseline tumor burden and survival?\",\"answer\":\"Larger baseline tumor burden correlated with shorter OS, but not with PFS. Tumor regression showed only a weak negative association with higher baseline tumor burden quartiles at first scan.\"}]","Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609) | PDF",1790093517,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5301f07e68438609e97a991483c17d08.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5c1eeed13a9eeb260559e47ade2005f.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8e2f3b5be6bb4b4e313c55b69668c5e.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88cf5b8d2bb27ab8ec46544061fabf10.webp",980,1287]